Renalytix AI Reports Strong Growth and Strategic Expansion

Renalytix AI Plc ( (RENXF) ) has released its Q4 earnings. Here is a breakdown of the information Renalytix AI Plc presented to its investors.

Renalytix AI Plc is a pioneering company in the field of bioprognosis for kidney health, focusing on early-stage chronic kidney disease risk assessment through its FDA-approved KidneyIntelX platform. The company has reported significant growth in its 2025 financial year, with a 30% increase in total revenues and a 37% rise in commercial testing volumes, driven by strategic partnerships and Medicare reimbursement for its KidneyIntelX.dkd test. Key financial highlights include a substantial reduction in administrative expenses by over 40% and a 54% decrease in underlying EBITDA loss, alongside successful capital raises totaling £18.5 million. Renalytix has also expanded its market presence with new partnerships, such as those with MVP Health Care and Tempus AI, enhancing its distribution network and supporting its growth strategy. Looking ahead, Renalytix is focused on further integrating its KidneyIntelX technology into electronic medical records, expanding its insurance payor coverage, and pursuing international market opportunities to continue its trajectory of growth and innovation in kidney disease management.